March 16 (Reuters) - Sanofi SA (SASY.PA), opens new tab said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by ...
The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...
The FINANCIAL — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on September 20 results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting ...
LONDON (Reuters) - A once-daily injection of Sanofi-Aventis's insulin drug Lantus controls blood sugar as effectively as Eli Lilly's Humalog, which needs to be taken three times daily, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results